# EDGAR Filing Document

**Accession Number:** 0001937993
**File Stem:** 0001213900-23-003025
**Filing Date:** 2023-1
**Character Count:** 2805
**Document Hash:** 02df530fae4085793292c84cfa2fd446
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-003025.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001213900-23-003025

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cadrenal Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001937993
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 880860746
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 822 A1A NORTH
- **STREET 2:** SUITE 300
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32082
- **BUSINESS PHONE:** 904-300-0701

**MAIL ADDRESS:**
- **STREET 1:** 822 A1A NORTH
- **STREET 2:** SUITE 300
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32082

![](image_001.jpg)

January 17, 2023

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission<br> Division of Corporation Finance<br> 100 F Street, N.E.<br> Washington, D.C. 20549

Attention: Dillon Hagius

---

| | |
|:---|:---|
| **Re:** | **Cadrenal Therapeutics, Inc.<br> Registration Statement on Form S-1, as amended<br> File No: 333-267562<br> Request for Acceleration** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cadrenal Therapeutics, Inc. (the "**Registrant**") hereby requests that the United States Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form S-1, as amended, File No. 333-267562 (the "**Registration Statement**"), to become effective on Thursday, January 19, 2023, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Jamie L. Plisner, Esq. of Blank Rome LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either Ms. Marlow or Ms. Plisner when this request for acceleration has been granted.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **CADRENAL THERAPEUTICS, INC.** | **CADRENAL THERAPEUTICS, INC.** |
| By: | /s/ Quang Pham |
| Name: | Quang Pham |
| Title: | Chairman of the Board and Chief Executive Officer |

---

cc: Leslie Marlow, Esq., Blank Rome LLP<br> Jamie L. Plisner, Esq., Blank Rome LLP